Wall Street analyst estimates for Centessa Pharmaceuticals plc (CNTA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.57 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-11 | $-0.40 | ||
| 2026-05-05 | $-0.52 | $-0.38 | -36.8% |
| 2026-03-31 | $-0.48 | $-0.37 | -29.2% |
| 2025-11-05 | $-0.41 | $-0.39 | -5.1% |
| 2025-08-12 | $-0.38 | $-0.35 | -8.6% |
| 2025-05-14 | $-0.20 | $-0.35 | +42.9% |
| 2025-03-24 | $-0.84 | $-0.38 | -121.1% |
| 2024-11-12 | $-0.37 | $-0.42 | +11.9% |
Valuation Ratios
| Price / Book | 12.76 |
| EV / EBITDA | -23.84 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $6.9M | 0 | $15.0M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | $6.9M | 0 | $15.0M |
| Research & Development | $4.3M | $9.3M | $96.3M | $155.1M | $124.4M | $150.2M | $172.2M |
| Selling, General & Admin | $790000 | $1.1M | $43.0M | $55.2M | $53.7M | $50.8M | $50.5M |
| Operating Expenses | $5.1M | $10.4M | $374.9M | $212.3M | $178.1M | $201.1M | $222.7M |
| Operating Income | -$5.1M | -$10.4M | -$374.9M | -$212.3M | -$171.3M | -$201.1M | -$207.7M |
| EBITDA | -$5.0M | -$10.3M | -$139.3M | -$209.5M | -$165.4M | -$221.9M | -$183.3M |
| Interest Expense | $118000 | $378000 | $2.5M | $7.3M | $9.9M | $10.1M | $11.5M |
| Pre-tax Income | -$5.1M | -$10.7M | -$381.8M | -$217.0M | -$176.1M | -$232.9M | -$195.7M |
| Income Tax | 0 | 0 | $114000 | -$747000 | -$25.1M | $2.8M | $1.8M |
| Net Income | -$5.3M | -$10.7M | -$381.9M | -$216.2M | -$151.1M | -$235.8M | -$197.5M |
| EPS | $-0.05 | $-0.08 | $-4.24 | $-2.31 | $-1.57 | $-2.06 | $-1.46 |
| EPS (Diluted) | $-0.05 | $-0.08 | $-4.24 | $-2.31 | $-1.57 | $-2.06 | $-1.46 |
| Shares Outstanding (Diluted) | $106.5M | $70.9M | $90.0M | $93.4M | $96.2M | $114.5M | $135.7M |
Price
| Price | $40.50 |
| Market Cap | $6.3B |
| Exchange | NASDAQ |
| Country | GB |
Related companies: CGEM · CMPX · DSGN · EWTX · GLUE · IPSC · IVA
Explore sector: Healthcare · Biotechnology
More sections of CNTA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks